One device.
Multiple markets.
Aceso Plasma's cold plasma technology addresses critical unmet needs across wound care, dermatology, and defense decontamination — three distinct markets driven by a single underlying mechanism of action.
Chronic Wound Care
$15B+ global market · Growing at ~7% CAGR
Chronic wounds — including diabetic ulcers, pressure ulcers, and venous leg ulcers — affect millions of patients globally and represent one of the most costly challenges in modern healthcare. Current treatments are slow, expensive, and frequently complicated by antibiotic-resistant infections that existing agents cannot overcome.
Aceso Plasma addresses the core problem directly. By reducing bacterial bioburden with ROS — without chemicals or heat — investigational studies observed accelerated wound healing and improved re-epithelization compared to untreated controls. Further research is ongoing to characterize the precise mechanisms involved.
Before
After
Pre-clinical investigational study imagery. Not indicative of clinical outcomes.
Accelerated healing in investigational studiesBy helping control microbial burden, Aceso may support the body's natural healing processes and promote progression through the normal stages of wound healing. Pre-clinical research observed approximately 50% reduction in healing time compared to untreated controls.
No resistance pathwayROS targets all microbial proteins simultaneously — effective against antibiotic-resistant ESKAPE pathogens where conventional antimicrobial agents cannot be used.
New CPT billing codesROS-based wound treatment is eligible for new CPT codes — supporting reimbursement pathways for clinical providers and improving the commercial adoption case.
Safe for healthy tissueZero negative cytotoxic effects on healthy host cells observed in investigational studies — even at extended treatment durations, allowing generous treatment plans without patient risk.
Dermatology
$18B+ dermatology devices market · Growing at ~12% CAGR
The high concentration of Reactive Oxygen Species generated by Aceso Plasma addresses the underlying drivers of inflammatory and infectious skin conditions — reducing bacterial load, modulating the inflammatory response, and supporting skin regeneration without systemic drugs or harsh topicals.
The device is currently available for use and has demonstrated early promise across a range of dermatological conditions in case studies, including eczema, psoriasis, shingles, and impetigo — offering a drug-free, non-invasive treatment option for conditions that are often poorly managed by conventional approaches.
Child eczema — 36 hours / 3 treatments. Pre-clinical case study imagery.
Eczema and psoriasisCase studies have reported reduction in discomfort associated with these conditions — with one pediatric eczema case showing marked improvement in 36 hours across just 3 treatments. These are preliminary observations and not substantiated clinical claims.
Shingles and impetigoROS-based treatment addresses both the infectious and inflammatory components of these conditions non-invasively — without the systemic side effects of conventional drug treatments.
Observed symptom relief in case studiesPreliminary case studies have documented reported improvements in discomfort associated with conditions such as poison ivy, mosquito bites, burns, and lacerations. These observations have not been substantiated through controlled clinical studies at this stage.
Non-pharmaceutical and non-invasiveNo systemic drugs, no harsh topicals, no harmful UV emissions — offering a treatment option with a favorable safety profile that does not rely on pharmaceutical agents for its primary mechanism.
Military Decontamination
$3.9B decontamination systems market · Growing at ~6% CAGR
Current decontamination solutions for military and surgical equipment rely on liquid chemicals, heat, or moisture — approaches incompatible with sensitive electronics, optics, and tactical gear. Aceso Plasma's plasma-based decontamination is a dry, waterless approach that leaves no residue — making it suited for equipment that cannot be exposed to conventional wet or chemical decontamination methods.
We are developing a dedicated Aceso Decontamination Chamber that concentrates plasma outputs in a self-contained enclosure, achieving 100% decontamination of MRSA and ESKAPE pathogens across multiple materials in proof-of-concept testing. Designed for both surgical suites and forward operating base deployment.
Chamber — external view
Chamber — internal grid
Aceso Decontamination Chamber — proof of concept prototype. Currently in engineering development.
Waterless — safe for sensitive equipmentNo moisture means no damage to electronics, optics, or precision instruments — critical for tactical gear, night vision, and advanced medical equipment that cannot be wetted.
100% MRSA and ESKAPE decontaminationProof-of-concept testing in chamber format achieved complete decontamination across multiple material types — including those used in surgical and tactical applications.
Chemical warfare agent neutralizationEdgewood Chemical Biological Center studies demonstrated up to 47.5% VX reduction at 240 seconds — with efficacy increasing proportionally with exposure time.
Mobile and field-deployableCompact chamber design is scalable and portable for forward operating base and surgical unit deployment — no infrastructure, consumables, or chemical supply chain required.
The Aceso Decontamination Chamber is currently in engineering development and is not yet available. FDA High-Level Disinfection Certification is being pursued. The current handheld Aceso Plasma device demonstrates the underlying ROS decontamination capability.
Three large markets.
One technology platform.
Aceso Plasma's single underlying ROS mechanism addresses significant commercial opportunities across three distinct and growing markets.
Chronic Wound Care
$15B+
Global market · 2025
↑ ~7% CAGR through 2032Driven by rising diabetes prevalence, aging populations, and growing antibiotic resistance — creating urgent demand for novel wound care solutions. North America holds ~37% market share.
Dermatology Devices
$18B+
Global market · 2025
↑ ~12% CAGR through 2029Rapid growth driven by increasing prevalence of eczema, psoriasis, and other inflammatory skin conditions combined with demand for non-pharmaceutical device-based treatment options.
Decontamination Systems
$3.9B
Global market · 2025
↑ ~6% CAGR through 2030Defense and military a key growth segment, with increasing CBRN preparedness investment and demand for waterless, dry decontamination solutions compatible with sensitive equipment that cannot tolerate liquid or chemical processes.
Interested in a specific
application area?
Whether you're a clinician, military medical officer, or investor — we'd love to connect and discuss how Aceso Plasma applies to your specific context.